Evidence map›Paper›PMID 35801263›Full record

ArticleJournal of veterinary internal medicine2022

Splenectomy in the management of primary immune-mediated hemolytic anemia and primary immune-mediated thrombocytopenia in dogs.

Jason P Bestwick, Barbara J Skelly, James W Swann, Barbara Glanemann, Nick Bexfield, Zeta Gkoka, David J Walker, Paolo Silvestrini, Sophie Adamantos, Mayank Seth and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of veterinary internal medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 5 countries.

Jason P Bestwick *Animal Health Trust, Newmarket, Suffolk, United Kingdom.ORCID https://orcid.org/0000-0002-0138-0565
Barbara J SkellyQueen's Veterinary School Hospital, University of Cambridge, Cambridge, United Kingdom.
James W SwannDepartment of Clinical Science and Services, The Royal Veterinary College, University of London, Hertfordshire, United Kingdom.
Barbara GlanemannDepartment of Clinical Science and Services, The Royal Veterinary College, University of London, Hertfordshire, United Kingdom.ORCID https://orcid.org/0000-0003-4830-7610
Nick BexfieldQueen's Veterinary School Hospital, University of Cambridge, Cambridge, United Kingdom.
Zeta GkokaAnderson Moores Veterinary Specialists, Winchester, United Kingdom.
David J WalkerAnderson Moores Veterinary Specialists, Winchester, United Kingdom.
Paolo SilvestriniSmall Animal Teaching Hospital, Institute of Veterinary Science, University of Liverpool, Neston, United Kingdom.ORCID https://orcid.org/0000-0003-3671-5350
Sophie AdamantosLangford Vets/University of Bristol, Bristol, North Somerset, United Kingdom.
Mayank SethAnimal Health Trust, Newmarket, Suffolk, United Kingdom.
James Warland *Animal Health Trust, Newmarket, Suffolk, United Kingdom.
Animal Health Trust · GBDermatology Specialists · USUniversity of Cambridge · GBUniversity of London · GBUniversity of Liverpool · GBWest Yorkshire Police · GB

Funding

Linnaeus Veterinary Limited
6 · The paper itself

Abstract

backgroundCurrent reports about the use of splenectomy for the management of immune-mediated hemolytic anemia (IMHA) or immune-mediated thrombocytopenia (ITP) or both in dogs are limited.

objectivesTo retrospectively describe the use of splenectomy as part of the management for IMHA, ITP, and concurrent IMHA and severe thrombocytopenia (CIST) in dogs. It was hypothesized that splenectomy would be beneficial in allowing for reduction of dose of immunosuppressive drugs or discontinuation in 1 or more of these groups. ANIMALS: Seventeen client-owned dogs (7 with IMHA, 7 with ITP, and 3 with CIST) were identified across 7 UK-based referral hospitals from a study period of 2005 to 2016.

methodsData were collected retrospectively via questionnaires and included information about diagnosis, management and treatment response before and after splenectomy. Based on clinical outcome, treatment with splenectomy as part of the management protocol was classified as either successful or unsuccessful.

resultsSix of 7 dogs with ITP were managed successfully with splenectomy as part of their management protocol (3 complete and 3 partial responses), although 1 subsequently developed suspected IMHA. Of the 7 dogs with IMHA, splenectomy was part of a successful management protocol in 4 dogs (2 complete and 2 partial responses). In the CIST group, 1 case (1/3) responded completely to management with splenectomy as part of the management protocol. CONCLUSIONS AND CLINICAL IMPORTANCE: Splenectomy was considered successful and well tolerated in most cases of isolated ITP. Whether there is a benefit of splenectomy in cases of IMHA and CIST could not be determined in the current study.

Indexed as

Anemia, Hemolytic, AutoimmuneDog DiseasesThrombocytopeniaAnimalsDogsRetrospective StudiesSplenectomyAIHAautoimmuneIMHAITPspleen

Identifiers

PMID35801263
PMCPMC9308443
OpenAlexW4284968340

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.